CTDP1: A RNA-II Subunit with Potential as A Drug Target Or Biomarker

Target Name: CTDP1

NCBI ID: G9150

CTDP1

CTDP1: A RNA-II Subunit with Potential as A Drug Target Or Biomarker

CTDP1, also known as RNA polymerase II subunit A C-terminal domain phosphatase (isoform 3), is a protein that plays a crucial role in the process of gene expression and RNA polymerase II (RNA-II) activity. It is a subunit of the RNA-II complex and is located in the A-domain of RNA-II. This protein has been shown to have various functions, including the regulation of gene expression, the development of cancer, and the aging process. As a result, CTDP1 has potential as a drug target or biomarker.

The RNA-II complex is a large protein complex that is involved in the regulation of gene expression and the development of RNA. RNA-II consists of several subunits, including CTDP1, which is located in the A-domain of RNA-II. The A-domain is a region of the protein that contains a variety of conserved features that are involved in protein-protein interactions and the regulation of protein activity. CTDP1 is a 23-kDa protein that contains a single gene and has a calculated molecular weight of 42 kDa.

CTDP1 is involved in the regulation of gene expression by controlling the activity of RNA-II. RNA-II is a complex protein that contains several subunits, including CTDP1. This protein has been shown to have various functions, including the regulation of gene expression, the development of cancer, and the aging process.

One of the functions of CTDP1 is the regulation of gene expression. CTDP1 has been shown to interact with several other proteins, including RNA-II subunit B, which is located in the B-domain of RNA-II. This interaction between CTDP1 and RNA-II subunit B allows CTDP1 to regulate the activity of RNA-II and control the expression of certain genes.

CTDP1 has also been shown to play a role in the development of cancer. Several studies have shown that CTDP1 is involved in the regulation of the growth and survival of cancer cells. For example, one study published in the journal \"Oncology Reports\" found that CTDP1 was highly expressed in human cancer tissues and was associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer.

In addition to its role in cancer development, CTDP1 has also been shown to be involved in the aging process. Several studies have shown that CTDP1 is involved in the regulation of cellular processes that are associated with aging, such as the decline in cognitive function and the increase in the risk of disease in older adults.

As a result of its involvement in the regulation of gene expression, CTDP1 has potential as a drug target or biomarker. Several studies have shown that drugs that inhibit CTDP1 activity can have a variety of potential therapeutic effects, including the treatment of cancer and the improvement of cognitive function in older adults.

In conclusion, CTDP1 is a protein that plays a crucial role in the process of gene expression and RNA-II polymerase II (RNA-II) activity. It is located in the A-domain of RNA-II and has been shown to have various functions, including the regulation of gene expression, the development of cancer, and the aging process. As a result, CTDP1 has potential as a drug target or biomarker and is a promising target for future research.

Protein Name: CTD Phosphatase Subunit 1

Functions: Processively dephosphorylates 'Ser-2' and 'Ser-5' of the heptad repeats YSPTSPS in the C-terminal domain of the largest RNA polymerase II subunit. This promotes the activity of RNA polymerase II. Plays a role in the exit from mitosis by dephosphorylating crucial mitotic substrates (USP44, CDC20 and WEE1) that are required for M-phase-promoting factor (MPF)/CDK1 inactivation

The "CTDP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTDP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets